Life Science Nation Newsletter  |  February 18, 2016  |  Issue 150

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Accelerator
Life Science Investor Mandates (Feb. 11 - Feb. 17)
Invests In Healthcare IT, Data Science and Synthetic Biology to Target Inefficiencies In Healthcare
Seeks Series A-B Deals In Liver Disease, CNS and Diabetes
Seeks Healthcare Opportunities Outside of Traditional Biotech Hubs
Raising New Fund to Invest In Diagnostics, Digital Health, Devices and Vaccines
In This Issue
LSN Videos
RESI San Francisco 2016 Investors Panel

Video Recap of RESI@TMCx 2015

By Dennis Ford, Founder & CEO, LSN

Sourcing quality assets is the key conundrum for life science investors. Using the LSN Company Platform, investors and strategic players can get visibility on 30,000 global early stage products. Many pharma scouting groups use this and other data tools to identify assets and vet the competitive landscape. The LSN Company Platform is a compelling tool, and LSN has also developed other tools and tactics to surface compelling life science technologies.

LSN's quarterly Redefining Early Stage Investments (RESI) Conference series features the RESI Innovation Challenge, which provides LSN a unique view into hundreds of companies every year that are actively seeking capital. These applicants virtually qualify themselves as being in the game, as the first great metric for investment is whether the team has decided to raise funds and can adequately pitch their product...

By Lucy Parkinson, Director of Research, LSN

On June 23rd, LSN will partner with MaRS Discovery District to create the first international Redefining Early Stage Investments event, RESI On MaRS in Toronto.

With MaRS on our horizon, it's time for Next Phase to take a look at where Canada's life science strengths lie. Using the LSN Company Platform, we took a look at a sample of almost 500 therapeutic assets under development in Canada.

While we found life science innovation in almost every corner of Canada, the startup companies in our sample were concentrated in Ontario, Quebec and British Columbia. These assets were spread across the full range of developmental phases, but with a noticeable skew toward early stage assets...


By Christine A. Wu, Research Analyst, LSN

On January 12, LSN gathered a panel of large medical device manufacturers at the RESI@JPM San Francisco Conference. Moderated by Greg Fleming, Investment Director of ALIAD, panelists from Becton Dickinson, Siemens Venture Capital, Abbott Ventures, and Johnson & Johnson discussed how they evaluate and engage with early stage medtech companies, their strategic approach to working with companies, and how early stage companies should approach them...